A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- Male
Research at a glance
Top areas of exploration
- Kidney Neoplasms , 39 publications
- Carcinoma, Renal Cell , 28 publications
- Nephrectomy , 20 publications
- Prostatic Neoplasms , 16 publications
Research activity
Active clinical trials
Bladder cancer is the 8th most common cancer in the ÍøºìºÚÁÏ Cancer Center catchment area and the 7th most common cancer presenting to UFÍøºìºÚÁÏ. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle…
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts…
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- Male
My publications
Filter publications
95 publications
2024
Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
Urologic oncology
•2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
The Journal of urology
•2024
Case report: A novel somatic SDHB variant in a patient with bladder paraganglioma.
Frontiers in endocrinology
•2023
Hyaluronan Metabolism in Urologic Cancers.
Advanced biology
•2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
European urology focus
•